What is the GIP receptor?
The GIP receptor is a G-protein-coupled receptor that binds glucose-dependent insulinotropic polypeptide (GIP) — an intestinal incretin hormone. Expressed on pancreatic beta cells and adipocytes; the second receptor arm of dual-incretin agonists like tirzepatide and triple agonists like.
What the research literature says
The GIP receptor is a Class B G-protein-coupled receptor expressed primarily on pancreatic beta cells (producing glucose-dependent insulin secretion), adipocytes (modulating adipose-tissue lipid metabolism), and several other tissues. Native GIP is a 42-amino-acid peptide secreted by intestinal K-cells in the proximal small intestine in response to nutrient intake.
The Willard tirzepatide pharmacology work established that tirzepatide engages the GIP receptor in a biased and imbalanced fashion — conformationally distinct from native GIP and producing a different downstream signalling profile (PMID 32730231). This biased agonism is the principal pharmacological distinction from the parallel GLP-1 receptor arm of the compound. The Thomas beta-cell function and insulin-sensitivity work characterised the clinical-pharmacology consequences (PMID 33236115).
An investigational triple agonist extends the GIP receptor engagement into the triple-agonist framework with the additional glucagon-receptor arm (Jastreboff phase 2, PMID 37366315; Rosenstock type 2 diabetes phase 2, PMID 37385280).
Why this matters in research context
The GIP receptor matters in peptide-research contexts as the second pharmacological arm of dual-incretin agonists. Researchers using tirzepatide for metabolic-research protocols should account for the biased GIP-receptor engagement when interpreting downstream pharmacology — the biased agonism means tirzepatide’s GIP arm may not extrapolate cleanly from native GIP research.
Related compounds
- Tirzepatide 10mg — dual GIP + GLP-1 agonist
Related research questions
References
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. [PMID 32730231]
- Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab 2021;106(2):388-396. [PMID 33236115]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.